Passive immunotherapy of cancer in animals and man

Steven A. Rosenberg, William D. Terry

Research output: Contribution to journalArticle


Immune depression or anergy in cancer patients has been well documented, and attempts to actively stimulate both nonspecific and specific antitumor immune reactions in cancer patients might well be thwarted by intrinsic defects in the ability of the host to respond. The passive administration of immune reagents such as serum, cells, or subcellular products that might be capable of reacting against the tumor independent of the host's immune competence has thus been an attractive area of investigation in tumor immunotherapy. Attempts to supply the tumor-bearing host, both animal and human, with normal serum or plasma (e.g., Moore et al., 1957; Albo et al., 1968) or normal allogeneic lymphocytes (e.g., Woodruff and Nolan, 1963; Symes et al., 1968; Moore and Gerner, 1970; Yonemoto and Terasaki, 1972) have been universally unsuccessful, and recent attempts have focused on the use of previously sensitized immune components.

Original languageEnglish (US)
Pages (from-to)323-388
Number of pages66
JournalAdvances in cancer research
Issue numberC
StatePublished - Jan 1 1977

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Passive immunotherapy of cancer in animals and man'. Together they form a unique fingerprint.

  • Cite this